ArticleFrontiers in medicine2025
Case Report: Adjunctive hemoadsorption therapy in a patient with Takotsubo cardiomyopathy and hyperinflammation.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Takotsubo cardiomyopathy (TCM) is a transient, stress-related cardiac dysfunction that mimics acute coronary syndrome and is typically seen in postmenopausal women. While emotional and physical stressors are common triggers, inflammatory or infectious stimuli have also been proposed, although the underlying mechanisms remain incompletely understood. In the context of critical illness, systemic inflammation may exacerbate cardiac dysfunction and contribute to multiorgan failure. Hemoadsorption has emerged as a promising adjunctive therapy option aimed at mitigating hyperinflammation by removing circulating cytokines and other inflammatory mediators, and has shown potential benefit in various inflammatory conditions. Case description: A 77-year-old woman with hypertension, diabetes, and a permanent pacemaker presented with acute dyspnea and subsequently experienced cardiac arrest. Post-resuscitation, she was found to have anterolateral ST elevations, apicomedial akinesis, and severely reduced LVEF (22%), consistent with Takotsubo cardiomyopathy. Despite appropriate antimicrobial therapy and supportive care, she developed worsening fever, marked hemodynamic instability, hyperlactatemia (14 mmol/L), atrial fibrillation, raising suspicion for a systemic hyperinflammatory response. Hemoadsorption therapy with CytoSorb was initiated in a stand-alone configuration, alongside corticosteroids and targeted temperature management. The patient showed marked improvement in hemodynamics, organ function, and urine output within 48 h, without the need for renal replacement therapy. She was later extubated and discharged home. Conclusion: This case highlights a rare presentation of suspected inflammation-triggered Takotsubo cardiomyopathy complicated by rapid clinical deterioration. The use of CytoSorb hemoadsorption was associated with stabilization of vital parameters and recovery of organ function. Although causality cannot be confirmed, this case supports the early consideration of hemoadsorption as a feasible and potentially beneficial adjunct in select critically ill patients with suspected hyperinflammation. Further research is needed to clarify its role in TCM and related syndromes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.